I have suffered optic nerve and retinal damage caused by glaucoma for more than 5 years, and my visual function has now improved by over 30% following treatment at WMC.

Ms. Maria Cristina, an elegant 75‑year‑old lady from Argentina, developed optic nerve and retinal damage due to glaucoma related to her age and physical condition. More than 5 years of progressive bilateral eye disease led to gradual vision loss. At present, her right eye only retains light perception, while her left eye can perceive blurry objects at close range with poor object recognition. Her right eye has a medical history of corneal ulcer and retinal detachment. A disc‑shaped silicone sheet was previously implanted to regulate intraocular pressure. Nevertheless, vision loss continued to progress. She is currently using Dorzolamide 2% / Timolol eye drops (Glaucotensil), Latanoprost 0.005% eye drops (LOUTEN), and Sodium Carboxymethylcellulose 0.5% eye drops (Carboximetilcelulsa Sodica 0.5%).

Over 5 years of severe deterioration in bilateral vision has filled Ms. Maria Cristina’s world with gloom, depression and confinement, and she appears much older. Hoping to live independently once more, to regain her once bright and colourful world, and to walk freely amid the green spaces and blue sky she loves, she resolved to seek the world’s most advanced medical treatment to fulfil her long‑cherished dream.

Dr. Wu is one of the world’s top clinical experts in stem‑cell therapy for a wide range of intractable and refractory ocular diseases. More than 20 years ago, he devoted himself to researching stem‑cell therapies for optic‑nerve and retinal disorders, cerebral palsy, ALS, sequelae of spinal‑cord injury, Parkinson’s disease, and post‑stroke sequelae. He has continuously upgraded his original, globally unique dual‑stem‑cell + CAST therapy, bringing benefits to numerous patients suffering from these conditions.

As the number of treated cases grew, Dr. Wu drew on his distinctive academic perspective to observe and explore the functional relationships among nerves, blood vessels, muscles, skin and other organs of the human body. Consequently, his stem‑cell protocols have safely and effectively addressed many complex medical conditions overlooked by other stem‑cell specialists, including multiple ophthalmic disorders that conventional medicine has long failed to cure.

When Dr. Wu was deeply engaged in treating intractable and refractory eye diseases with his original stem‑cell clinical techniques, glaucoma was once regarded as a contraindication for his treatments. This left many ophthalmic patients with concomitant glaucoma unable to access stem‑cell therapy. Drawing on more than 40 years of clinical medical knowledge and experience, Dr. Wu persistently investigated this “grey‑zone” clinical challenge and finally solved this world‑level medical puzzle. Today, with his original dual‑stem‑cell + CAST therapy, Dr. Wu can treat patients suffering from glaucoma alongside other intractable and refractory eye diseases. Averagely, their visual function achieves clear improvement of more than 30% during hospitalisation.

Recently, Ms. Maria Cristina was fortunate to be admitted to Wu Medical Center and received Dr. Wu’s remarkable stem‑cell therapy for her ocular conditions.

Within only 2 weeks of hospitalisation, Ms. Maria Cristina achieved visual‑function improvement, with overall functional gains averaging over 30%.

Before treatment: Her slight opacity was observed in both pupils.
After treatment: The appearance of both pupils became clearer, largely consistent with normal eyes.

Before treatment: At 40 cm in front of the standard visual acuity chart, she could only vaguely recognise the third line (equivalent to 0.1 at 3 metres), corresponding to a decimal visual acuity of 0.01; she also had poor colour‑discrimination ability.
After treatment: Her left eye gained elementary object‑recognition capacity together with partial colour‑discrimination ability. She can count fingers presented at 50 cm, accurately identify object colours, and sometimes make out posters. At 115 cm from the standard visual acuity chart, she can recognise the third line (equivalent to 0.1 at 3 metres), corresponding to a decimal visual acuity of 0.03.

Before treatment: Her right eye had only light perception without the capacity to localise light sources.
After treatment: Her right eye can detect and accurately localise light sources presented 1 metre away on the temporal side.

Before treatment: For the left eye: no optic‑disc oedema, ill‑defined disc margins, pale‑yellow disc colour, present fovea centralis with poor foveal reflex, arteriovenous ratio 1:4. For the right eye: no optic‑disc oedema, relatively blurred disc margins, pale optic disc, fovea centralis barely identifiable, arteriovenous ratio 1:4.
After treatment: Funduscopic findings improved compared with admission: the fundus changed from pale white on admission to light red; the bilateral arteriovenous ratio improved from 1:4 at admission to 1:2.

We will keep following up on Ms. Maria Cristina’s subsequent treatment and rehabilitation training, and believe she will achieve faster and better recovery!

We hope to support more patients like Ms. Maria Cristina living with combined optic‑nerve‑and‑retinal damage and glaucoma to experience the cutting‑edge dual‑stem‑cell + CAST therapy at WMC, which differs from conventional medicine. May their ocular symptoms be alleviated, their visual function restored, their quality of life enhanced, so that they can confidently return to their colourful lives.

To learn more information of Ms. Maria Cristina’s patient story, please refer to the following link:
Maria Cristina-Optic nerve and retinal injury; Glaucoma-(Argentine)